Alexion
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| rareDisease | ×0.89 | 3 |
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 3 disclosed transactions, Alexion concentrates its licensing activity in RareDisease. Alexion pays a 0.89x discount to market median, with the strongest premiums in RareDisease (0.89x). Their most common deal structure is Acquisition, with an average disclosed value of $1.2B. Most recent activity: 2020.
Premium by therapeutic area
How Alexion pays relative to peer medians in each TA
Pipeline coverage & gaps
Alexion has disclosed activity in 1 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| AcquisitionPrimary | 3 | $913M | $1.2B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2020 | Andexanet alfa (Andexxa) | Portola Pharmaceuticals | Reversal of Factor Xa Inhibitors | approved | $1.4B | $1.4B |
| 2019 | Danicopan (Factor D inhibitor) | Achillion Pharmaceuticals | Paroxysmal Nocturnal Hemoglobinuria | phase_2 | $930M | $930M |
| 2018 | SYNT001 (anti-FcRn) | Syntimmune | Warm Autoimmune Hemolytic Anemia | phase_1 | $400M | $1.2B |
How this is computed
For each Alexion deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 0.892, clamped to [0.7, 1.5].